Levodopa-induced dyskinesia and rotational behavior in hemiparkinsonian rats: Independent features or components of the same phenomenon?

Behavioural Brain Research

Volumn 170, Issue 2, 2006, Pages 337-341

  Konitsiotis, Spiridon ^a   Tsironis, Christos ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

6 Hydroxydopamine; Dyskinesia; Levodopa; Parkinsonism; Rotational behavior

Indexed keywords

LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CORRELATION ANALYSIS; DYSKINESIA; HEAD MOVEMENT; INVOLUNTARY MOVEMENT; LIMB MOVEMENT; MALE; NECK; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; TRUNK;

ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; LEVODOPA; MALE; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR; ROTATION; TIME FACTORS;

EID: 33646500078     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2006.02.030     Document Type: Article

References (25)

1. Blanchet P.J., Calon F., Morissette M., Hadj Tahar A., Belanger N., Samadi P., et al. Relevance of the MPTP-primate model in the study of dyskinesia priming mechanisms. Parkinsonism Relat Disord 10 (2004) 297-304
2. Cenci M.A., Whishaw I.Q., and Schallert T. Animal models of neurological deficits: how relevant is the rat?. Nat Rev Neurosci 3 (2002) 574-579
3. Chase T.N., Konitsiotis S., and Oh J.D. Striatal molecular mechanisms and motor dysfunction in Parkinson's disease. Adv Neurol 86 (2001) 355-360
4. Deumens R., Blokland A., and Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 175 (2002) 303-317
5. Di Chiara G.D., Morelli M., Barone P., and Pontieri F. Priming as a model of behavioral sensitization. Dev Pharmacol Ther 18 (1992) 223-227
6. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., et al., Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 351 (2004) 2498-2508
7. Goldstein M., Battista A.F., Ohmoto T., Anagnoste B., and Fuxe K. Tremor and involuntary movements in monkeys: effect of l-dopa and of a dopamine receptor stimulating agent. Science 179 (1973) 816-817
8. Henry B., Crossman A.R., and Brotchie J.M. Characterization of enhanced behavioral responses to l-dopa following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol 151 (1998) 334-342
9. Jenner P., Boyce S., and Marsden C.D. Receptor changes during chronic dopaminergic stimulation. J Neural Transm 27 (1988) 161-175
10. Lee C.S., Cenci M.A., Schulzer M., and Bjorklund A. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 123 (2000) 1365-1379
11. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., and Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 151 (2002) 120-132
12. Marras C., Lang A., Krahn M., Tomlinson G., Naglie G., and Parkinson Study Group. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations. Mov Disord 19 (2004) 22-28
13. Marsden C. Problems with long term-levodopa therapy for Parkinson's disease. Clin Neuropharmacol 17 (1994) S32-S44
14. Papa S.M., Engber T.M., Kask A.M., and Chase T.N. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 662 (1994) 69-74
15. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 5th ed. 2005.
16. Robinson T.E., and Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 396 (1986) 157-198
17. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., and Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39 (2000) 777-787
18. Schneider J.S. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol Biochem Behav 34 (1989) 193-196
19. Schultz W., and Ungerstedt U. Striatal cell supersensitivity to apomorphine in dopamine-lesioned rats correlated to behaviour. Neuropharmacology 17 (1978) 349-353
20. Schwarting R.K., and Huston J.P. Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog Neurobiol 49 (1996) 215-266
21. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand 367 (1971) 69-93
22. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5 (1968) 107-110
23. Ungerstedt U. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand 367 Suppl. (1971) 95-122
24. Verhagen Metman L., Locatelli E.R., Bravi D., Mouradian M.M., and Chase T.N. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology 48 (1997) 369-372
25. Voon V. Repetition, repetition, and repetition: compulsive and punding behaviors in Parkinson's disease. Mov Disord 19 (2004) 367-370